Skip to main content
Medical information Clinical review pending

Genetic Testing

WWOX Gene Spinocerebellar Ataxia Type 12 Autosomal Recessive Genetic Test

This genetic test identifies mutations in the WWOX gene associated with Spinocerebellar Ataxia Type 12, a neurological disorder affecting coordination and balance. It uses Next-Generation Sequencing (NGS) technology.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or Saliva sample (collection kit provided). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No specific fasting is required. Avoid strenuous activity before sample collection if blood is drawn. Follow any specific instructions provided by the laboratory.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the WWOX Gene Spinocerebellar Ataxia Type 12 Autosomal Recessive Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms of progressive ataxia (loss of coordination, unsteady gait)
  • ✓Family history of Spinocerebellar Ataxia Type 12
  • ✓Neurological symptoms suggestive of a genetic disorder
  • ✓Assessment of risk for autosomal recessive neurological conditions
  • ✓Confirmation of diagnosis in suspected cases
02

In plain language

What this test helps you understand

Identifies specific mutations in the WWOX gene associated with Spinocerebellar Ataxia Type 12, aiding in diagnosis and risk assessment for individuals with relevant symptoms or family history.
The WWOX Gene Spinocerebellar Ataxia Type 12 Autosomal Recessive NGS Genetic DNA Test is a specialized genetic analysis used to understand neurological conditions linked to the WWOX gene. This test utilizes Next-Generation Sequencing (NGS) technology to detect specific genetic mutations that can lead to spinocerebellar ataxia type 12. This condition is characterized by the progressive loss of coordination and balance.

This test focuses on identifying mutations within the WWOX gene known to cause spinocerebellar ataxia type 12. By examining an individual's DNA, healthcare providers can assess their risk for developing this condition. Early identification allows for proactive management and potential interventions.

Individuals experiencing symptoms like loss of coordination, unsteady walking, or difficulties with fine motor skills may benefit from this test. A family history of neurological disorders is also a factor to consider.

Benefits of this test include early detection of genetic risk factors for spinocerebellar ataxia type 12, enabling informed decisions about health management. It also facilitates genetic counseling to understand potential implications for the individual and their family.

Results will indicate the presence or absence of mutations associated with spinocerebellar ataxia type 12. A genetic counselor can help interpret these results and discuss appropriate next steps, which may include lifestyle adjustments or monitoring for symptoms.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific fasting is required. Avoid strenuous activity before sample collection if blood is drawn. Follow any specific instructions provided by the laboratory.
SampleBlood sample (EDTA tube) or Saliva sample (collection kit provided). Confirm specific requirements with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) of the WWOX gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the WWOX gene. It does not detect mutations in other genes that may cause similar symptoms. A negative result does not completely rule out Spinocerebellar Ataxia Type 12 or other genetic conditions. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Spinocerebellar Ataxia Type 12 is a rare, inherited neurological disorder characterized by progressive problems with coordination and balance.
The test is performed using Next-Generation Sequencing (NGS) on a sample of your blood or saliva to analyze the WWOX gene.
Individuals with symptoms like loss of coordination, unsteady gait, or a family history of similar neurological conditions should discuss testing with their doctor.
Results indicate whether specific mutations in the WWOX gene associated with Spinocerebellar Ataxia Type 12 were found. A genetic counselor can help interpret the results.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp